IP Library Granted Patent US 8,440,445
Granted Patent B2
US 8,440,445 · App. 10/869,313 · Granted May 14, 2013

Neutral protease (NP) and product by using neutral protease for tissue dissociation as well as method for the production thereof

Inventors: Manfred Kurfürst (Moorrege, DE); Christian Raemsch (Uetersen, DE); Nicole Raemsch-Guenther (Uetersen, DE); Olaf Friedrich (Tornesch, DE); Silke Huettler (Uetersen, DE); Daniel Brandhorst (Linden, DE); Thierry Berney (Arenthon, FR); Pascal Bucher (Geneva, CH); Heide Brandhorst (Linden, DE)
Assignee: Nordmark Arzneimittel GmbH & Co. KG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,440,445
App. No.
10/869,313
Granted
May 14, 2013
Kind
B2
Abstract

The use of a neutral protease (NP) together with a collagenase consists in that a neutral protease which is not contained in a collagenase enzyme preparation and which is not produced by a recombinant production ia mixed before the beginning of a tissue dissociation with a collagenase or a collagenase enzyme preparation with an individual dosage of the quantitative proportions of neutral protease and collagenase for improving the isolation results with respect to yield, viability and integrity of the cells.

Claims (2)

1. A method for production of a two component product consisting of a neutral protease (NP) and a collagenase, the method comprising (i) determining a mixing ratio of NP to collagenase needed for isolation of islets of Langerhans from a pancreatic tissue, and (ii) mixing a separately prepared A component with a separately prepared B component in the mixing ratio directly before combining the product with the pancreatic tissue to be dissociated, wherein the A component is a completely purified neutral protease (NP) from Clostridium histolyticum which is not contained in a collagenase enzyme preparation and which is not produced by a recombinant production, and the B component is a purified or partially purified collagenase.

2. The method according to claim 1 , wherein the mixing ratio of component A to component B is 3% (w/w), 6% (w/w), 12% (w/w), or 24% (w/w).

Assignments (5)
CHANGE OF NAME Recorded Sep 28, 2021
From: NORDMARK ARZNEIMITTEL GMBH & CO. KG
To: NORDMARK ARZNEIMITTEL HOLDING GMBH & CO. KG
Reel/Frame 057630/0614 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2021
From: NORDMARK ARZNEIMITTEL HOLDING GMBH & CO. KG
To: NORDMARK PHARMA GMBH
Reel/Frame 057484/0363 →
CHANGE OF NAME Recorded Sep 15, 2021
From: NORDMARK ARZNEIMITTEL GMBH & CO. KG
To: NORDMARK ARZNEIMITTEL HOLDING GMBH & CO. KG
Reel/Frame 057517/0496 →
CHANGE OF NAME Recorded Sep 13, 2021
From: ORDMARK ARZNEIMITTEL HOLDING GMBH & CO. KG
To: NORDMARK PHARMA GMBH
Reel/Frame 057584/0374 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2005
From: KURFURST, MANFRED; RAEMSCH, CHRISTIAN; RAEMSCH-GUENTHER, NICOLE; FRIEDRICH, OLAF; HUETTLER, SILKE; BRANDHORST, DANIEL; BERNEY, THIERRY; BUCHER, PASCAL; BRANDHORST, HEIDE
To: NORDMARK ARZNEIMITTEL GMBH & CO. KG
Reel/Frame 016560/0628 →
Priority Claims (1)
DE 103 31 171 · Jul 9, 2003 · national
Continuity (1)
Related Publication 20050142632A1 · Jun 30, 2005